Compare Citius Pharmaceuticals Inc (CTXR) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Oxford Lane Capital Corp trades at $9.14 (market cap $891.54M). The key difference: Oxford Lane Capital Corp is far larger — about 60.9× Citius Pharmaceuticals Inc's market cap, and Oxford Lane Capital Corp pays a 26.29% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | OXLC | |
|---|---|---|
Market Cap | $14.64M | $891.54M |
Sector | Health | Financials |
52-Week High | $1.82 | $20.80 |
52-Week Low | $0.53 | $8.15 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 26.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
OXLC trades at $9.19, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. The company reported a net income margin of 100.85% for 2025, but earnings misses and a sharp revenue decline to -$580M in 2026 highlight volatility. Recent news includes dividend declarations and a net asset value update from Oxford Lane Capital on June 15, 2026.
Outlook is cautious due to inconsistent earnings and high yield sustainability concerns. Risks include NAV decay and competitive pressures, while opportunities lie in dividend income. Analyst consensus is split, with 50% buy ratings but significant sell coverage citing fund performance issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
